Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rosiglitazone × Sarcoma × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 3 Endocrine 2 Dermatologic 2 Sarcoma 1 Lymphoid 1 Gastrointestinal 1 CNS 1

Conditions

Sarcoma 1 Liposarcoma 1

Interventions

Cyclophosphamide 89 Doxorubicin 85 Radiotherapy 80 Temozolomide 64 Ifosfamide 51 Filgrastim 51 Bevacizumab 51 Etoposide 45 Imatinib Mesylate 40 Gemcitabine 38 Vincristine 36 pembrolizumab 32 pazopanib 32 Methotrexate 28 Irinotecan 28 Nivolumab 27 fludarabine phosphate 26 Peripheral Blood Stem Cell Transplantation 26 Carboplatin 26 Magnetic Resonance Spectroscopy 24 Cisplatin 24 Trabectedin 23 Melphalan 23 Docetaxel 23 Busulfan 23 Paclitaxel 22 Sirolimus 21 apatinib 20 Specimen Handling 19 Rituximab 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00004180 2023-06-26

Rosiglitazone in Treating Patients With Liposarcoma

Dana-Farber Cancer Institute

Phase 2 Completed

Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡